About Veracyte Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.veracyte.com/
Frequently Asked Questions
What is the 52-week range for VCYT?
The 52-week high is $60.91 and the 52-week low is $29.455.
What is the P/E ratio for VCYT?
The Price to Earnings (P/E) ratio is 31.03.
What is the dividend yield for VCYT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 8.64%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 20.37%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.54.
Analyst Recommendation Trends
Wall Street analyst consensus for VCYT over the last few months:
Latest VCYT News
Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data
Veracyte (VCYT) is back in focus after new phase III data on its Decipher Prostate Genomic Classifier showed it can help identify which intermediate-risk prostate cancer patients benefit most from adding short-term hormone therapy. Investors have seen momentum cool in recent weeks, with Veracyte’s share price falling 4.0% on the day and 9.0% over the past week, while the 90 day share price return is down 22.6%. Yet the 1 year total shareholder return of 24.0% and 3 year total shareholder...
Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026
Veracyte, Inc. recently presented retrospective ancillary Phase III NRG/RTOG 0815 trial data at the 2026 ASTRO meeting, showing that its Decipher Prostate Genomic Classifier can stratify which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy to dose-escalated radiation, with Level 1B1 prognostic and predictive evidence. The findings suggest Decipher could help physicians better balance treatment benefit against the metabolic and...
Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?
Veracyte (NasdaqGM:VCYT) reported new phase III data showing its Decipher Prostate Genomic Classifier can guide hormone therapy use with radiation in intermediate-risk prostate cancer. The phase III trial provided prospective evidence that Decipher can help identify which patients are more likely to benefit from adding hormone therapy to radiation treatment. Findings suggest Decipher may extend its role from prognosis to predicting treatment benefit, potentially influencing how clinicians...
Neogen Stock Rallies 83% YTD: What's Driving the Surge?
NEOG's 83% YTD rally reflects Food Safety momentum, Petrifilm expansion, solutions-based selling and a growing product pipeline.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
Should You Continue to Hold IART Stock in Your Portfolio?
Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO)
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.
Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026
Cathie Wood Makes $64 Million Bet on Two Stocks
The latest trades reveal where Wood sees opportunity
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GEHC's record backlog, strong orders and AI-enabled innovations offer growth potential, while inflation and China remain key risks.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensificationSOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Societ
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow
Veracyte (VCYT) offers strong growth, high profitability, solid health, mixed valuation and supportive cash flow for affordable growth investors.
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now
XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
GEHC Launches CareIntellect AI Tool to Optimize Hospital Operations
GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.
Should Investors Add EYE Stock to Their Portfolios Now?
National Vision's premium-product demand and stronger customer mix support growth, but rising costs and vendor dependence remain key risks for investors.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Veracyte, Inc. (VCYT) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 7:00 AM EDTCompany ParticipantsMarc Stapley - CEO &...
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journeySOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfoli
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
Should You Continue to Hold ALGN Stock in Your Portfolio?
Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
Is This the Right Time to Add Neogen Stock to Your Portfolio?
NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.
PACS Expands Florida Footprint With 32-Facility Acquisition
PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Leite John | -4,015 | $40 | $160,600 |
| 2026-09-14 | Holstein Jens | -5,000 | $40.9494 | $204,747 |
| 2026-09-04 | McGuire Annie | -1,100 | $43.6718 | $48,039 |
| 2026-09-04 | McGuire Annie | -2,154 | $42.7916 | $92,173 |
| 2026-09-04 | Chambers Rebecca | -1,175 | $43.714 | $51,364 |
| 2026-09-04 | Chambers Rebecca | -2,477 | $42.8059 | $106,030 |
| 2026-09-04 | Febbo Phillip G. | -2,705 | $43.6618 | $118,105 |
| 2026-09-04 | Febbo Phillip G. | -10,405 | $42.8933 | $446,305 |
| 2026-09-02 | Leite John | -3,961 | $44.88 | $177,770 |
| 2026-09-02 | McGuire Annie | -3,215 | $44.88 | $144,289 |
| 2026-09-02 | Chambers Rebecca | -3,603 | $44.88 | $161,703 |
| 2026-09-02 | Febbo Phillip G. | -3,639 | $44.88 | $163,318 |
| 2026-09-02 | Wygant Jonathan | -1,361 | $44.88 | $61,082 |
| 2026-09-02 | Stapley Marc | -8,782 | $44.88 | $394,136 |
| 2026-09-01 | Bhanji Muna | -1,864 | $42.97 | $80,096 |
| 2026-06-18 | EASTHAM KARIN | -529 | $53.5504 | $28,328 |
| 2026-06-18 | EASTHAM KARIN | -3,200 | $52.7832 | $168,906 |
| 2026-06-11 | Miller Thomas F. | +5,272 | - | - |
| 2026-06-11 | Barr Eliav | +5,272 | - | - |
| 2026-06-11 | Bhanji Muna | +5,272 | - | - |
| 2026-06-11 | Holstein Jens | +5,272 | - | - |
| 2026-06-11 | Shafer David Brent | +5,272 | - | - |
| 2026-06-11 | EPSTEIN ROBERT S | +5,272 | - | - |
| 2026-06-11 | EASTHAM KARIN | +5,272 | - | - |
| 2026-06-11 | JONES EVAN/ FA | +5,272 | - | - |
| 2026-06-04 | Leite John | -13,975 | $50.0703 | $699,732 |
| 2026-06-04 | McGuire Annie | -1,776 | $50.1168 | $89,007 |
| 2026-06-04 | McGuire Annie | -1,400 | $49.3061 | $69,029 |
| 2026-06-04 | Chambers Rebecca | -1,961 | $50.0913 | $98,229 |
| 2026-06-04 | Chambers Rebecca | -1,600 | $49.2836 | $78,854 |
| 2026-06-04 | Stapley Marc | -138,051 | - | - |
| 2026-06-04 | Stapley Marc | -138,051 | $50.1234 | $6,919,585 |
| 2026-06-04 | Stapley Marc | +138,051 | $36.6 | $5,052,667 |
| 2026-06-02 | Leite John | -4,059 | $47.8 | $194,020 |
| 2026-06-02 | McGuire Annie | -3,292 | $47.8 | $157,358 |
| 2026-06-02 | Chambers Rebecca | -3,693 | $47.8 | $176,525 |
| 2026-06-02 | Febbo Phillip G. | -3,730 | $47.8 | $178,294 |
| 2026-06-02 | Wygant Jonathan | -1,361 | $47.8 | $65,056 |
| 2026-06-02 | Stapley Marc | -9,012 | $47.8 | $430,774 |
| 2026-05-22 | Wygant Jonathan | -24,000 | - | - |
| 2026-05-22 | Wygant Jonathan | -24,000 | $45.401 | $1,089,624 |
| 2026-05-22 | Wygant Jonathan | +24,000 | $24.8 | $595,200 |
| 2026-05-20 | EPSTEIN ROBERT S | -10,000 | $44.0129 | $440,129 |
| 2026-05-06 | McGuire Annie | -5,102 | $40 | $204,080 |
| 2026-05-06 | McGuire Annie | -5,102 | $38.05 | $194,131 |
| 2026-04-10 | Haas Kevin Richard | +44,221 | - | - |
| 2026-03-06 | Leite John | +6,578 | - | - |
| 2026-03-06 | Leite John | +36,181 | - | - |
| 2026-03-06 | McGuire Annie | +26,314 | - | - |
| 2026-03-06 | McGuire Annie | +32,892 | - | - |
| 2026-03-06 | Chambers Rebecca | +13,157 | - | - |
| 2026-03-06 | Chambers Rebecca | +36,181 | - | - |
| 2026-03-06 | Febbo Phillip G. | +6,578 | - | - |
| 2026-03-06 | Febbo Phillip G. | +29,603 | - | - |
| 2026-03-06 | Wygant Jonathan | +10,525 | - | - |
| 2026-03-06 | Stapley Marc | +92,099 | - | - |
| 2026-03-04 | Leite John | -5,260 | $35.1868 | $185,083 |
| 2026-03-04 | McGuire Annie | -1,664 | $36.3393 | $60,469 |
| 2026-03-04 | McGuire Annie | -4,994 | $35.2936 | $176,256 |
| 2026-03-04 | Chambers Rebecca | -13,941 | $36.3288 | $506,460 |
| 2026-03-04 | Chambers Rebecca | -4,400 | $35.5476 | $156,409 |
| 2026-03-04 | Stapley Marc | -26,279 | $36.2787 | $953,368 |
| 2026-03-04 | Stapley Marc | -19,244 | $35.5553 | $684,226 |
| 2026-03-02 | Leite John | -7,517 | $36.01 | $270,687 |
| 2026-03-02 | McGuire Annie | -6,902 | $36.01 | $248,541 |
| 2026-03-02 | Chambers Rebecca | -7,234 | $36.01 | $260,496 |
| 2026-03-02 | Febbo Phillip G. | -13,425 | $36.1586 | $485,429 |
| 2026-03-02 | Febbo Phillip G. | -6,035 | $36.01 | $217,320 |
| 2026-03-02 | Wygant Jonathan | -3,006 | $36.01 | $108,246 |
| 2026-03-02 | Stapley Marc | -19,455 | $36.01 | $700,575 |
| 2026-02-26 | Leite John | -8,905 | $38.75 | $345,069 |
| 2026-02-26 | Leite John | +47,149 | - | - |
| 2026-02-26 | McGuire Annie | -10,867 | $38.75 | $421,096 |
| 2026-02-26 | McGuire Annie | +50,999 | - | - |
| 2026-02-26 | Chambers Rebecca | -12,049 | $38.75 | $466,899 |
| 2026-02-26 | Chambers Rebecca | +59,324 | - | - |
| 2026-02-26 | Febbo Phillip G. | -24,486 | $38.75 | $948,833 |
| 2026-02-26 | Febbo Phillip G. | +71,806 | - | - |
| 2026-02-26 | Stapley Marc | -35,841 | $38.75 | $1,388,839 |
| 2026-02-26 | Stapley Marc | +139,074 | - | - |
| 2025-12-16 | McGuire Annie | -100 | $43.68 | $4,368 |
| 2025-12-16 | McGuire Annie | -10,639 | $43.1277 | $458,836 |
| 2025-12-05 | EASTHAM KARIN | -10,000 | - | - |
| 2025-12-05 | EASTHAM KARIN | -10,000 | - | - |
| 2025-12-05 | EASTHAM KARIN | -800 | $46.5898 | $37,272 |
| 2025-12-05 | EASTHAM KARIN | -12,808 | $45.837 | $587,080 |
| 2025-12-05 | EASTHAM KARIN | -6,392 | $44.5199 | $284,571 |
| 2025-12-05 | EASTHAM KARIN | +10,000 | $7.6 | $76,000 |
| 2025-12-05 | EASTHAM KARIN | +10,000 | $7.94 | $79,400 |
| 2025-12-04 | Leite John | -1,278 | $47.51 | $60,718 |
| 2025-12-04 | McGuire Annie | -702 | $47.51 | $33,352 |
| 2025-12-04 | McGuire Annie | -720 | $47.0955 | $33,909 |
| 2025-12-04 | Chambers Rebecca | -4,741 | $47.2493 | $224,009 |
| 2025-12-04 | Chambers Rebecca | -8,537 | $46.6143 | $397,946 |
| 2025-12-04 | Stapley Marc | -3,220 | $47.3485 | $152,462 |
| 2025-12-04 | Stapley Marc | -4,448 | $46.9005 | $208,613 |
| 2025-12-02 | Leite John | -2,900 | $46.16 | $133,864 |
| 2025-12-02 | McGuire Annie | -3,052 | $46.16 | $140,880 |
| 2025-12-02 | Chambers Rebecca | -3,384 | $46.16 | $156,205 |
| 2025-12-02 | Febbo Phillip G. | -2,955 | $46.16 | $136,403 |
| 2025-12-02 | Wygant Jonathan | -1,325 | $46.16 | $61,162 |
| 2025-12-02 | Stapley Marc | -7,914 | $46.16 | $365,310 |
| 2025-11-25 | Leite John | -2,808 | $50 | $140,400 |
| 2025-11-25 | JONES EVAN/ FA | -1,106 | $50.2493 | $55,576 |
| 2025-11-20 | Holstein Jens | -1,460 | $43.2095 | $63,086 |
| 2025-11-20 | Holstein Jens | -7,049 | $42.4765 | $299,417 |
| 2025-11-20 | Holstein Jens | -1,491 | $40.9526 | $61,060 |
| 2025-11-10 | Wygant Jonathan | -5,102 | $42.3321 | $215,978 |
| 2025-11-07 | Wygant Jonathan | -5,818 | $40.2078 | $233,929 |
| 2025-11-05 | McGuire Annie | -6,466 | $40 | $258,640 |
| 2025-11-05 | Chambers Rebecca | -7,000 | $41 | $287,000 |
| 2025-11-05 | EASTHAM KARIN | -9,674 | $40.0239 | $387,191 |
| 2025-11-05 | JONES EVAN/ FA | -10,000 | - | - |
| 2025-11-05 | JONES EVAN/ FA | -10,000 | - | - |
| 2025-11-05 | JONES EVAN/ FA | -10,000 | - | - |
| 2025-11-05 | JONES EVAN/ FA | -657 | $46.3756 | $30,469 |
| 2025-11-05 | JONES EVAN/ FA | -24,296 | $45.7273 | $1,110,990 |
| 2025-11-05 | JONES EVAN/ FA | -5,872 | $45.0682 | $264,640 |
| 2025-11-05 | JONES EVAN/ FA | -10,837 | $43.8038 | $474,702 |
| 2025-11-05 | JONES EVAN/ FA | -1,126 | $43.0329 | $48,455 |
| 2025-11-05 | JONES EVAN/ FA | -408 | $41.7431 | $17,031 |
| 2025-11-05 | JONES EVAN/ FA | +10,000 | $7.6 | $76,000 |
| 2025-11-05 | JONES EVAN/ FA | +10,000 | $7.94 | $79,400 |
| 2025-11-05 | JONES EVAN/ FA | +10,000 | $5.28 | $52,800 |
| 2025-10-28 | Wygant Jonathan | +2,886 | - | - |
| 2025-10-06 | Febbo Phillip G. | -8,349 | $36.0174 | $300,709 |